Dr James Andrews will act as principal investigator for the study. Dr Andrews is a founding partner and medical director for the Andrews Institute in Gulf Breeze, Florida.
This milestone adds to ProTrials’ successful track record in supporting ophthalmology studies investigating new treatments for a broad range of eye conditions, from age-related macular degeneration (AMD) to
After a thorough evaluation process of various commercially available technologies, Surrey CRC selected Promasys technology to manage its clinical research activities. Promasys ranked highest across all categories including
ESR, a common laboratory test and measure of inflammation, describes the rate at which red blood cells (RBC) travel through anti-coagulated blood. When an inflammatory process is present,
The settlements permit the defendants to begin selling generic versions of Gralise on 1 January 2024, or earlier under certain circumstances. The patent litigation continues against Actavis, the
These patents will provide protection in Japan until 2030. Including these patents, Advaxis now has well over 40 patents issued and over 40 patents pending worldwide, all covering
These data will be presented at the 29th Annual European Association of Urology (EAU) Congress taking place from 11 April to 15 April 2014 in Stockholm, Sweden. Dendreon
Results from the SAPPHIRE-II study were presented at the congress on 10 April 2014. Additionally, results from both the SAPPHIRE-I and SAPPHIRE-II studies have been published on-line in
This product is the generic version of FROVA®, which is used to treat acute migraine headaches in adults. As a result of the decision, the Court has vacated
This is in addition to the South Okanagan producing facility currently under evaluation. The parties have agreed to an exclusive 45-day negotiating period. There is no guarantee that
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.